151 related articles for article (PubMed ID: 37079225)
1. Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer.
Kashiwa M; Matsushita R
Int J Clin Pharm; 2023 Aug; 45(4):875-883. PubMed ID: 37079225
[TBL] [Abstract][Full Text] [Related]
2. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan.
Tsukiyama I; Ejiri M; Yamamoto Y; Nakao H; Yoneda M; Matsuura K; Arakawa I; Saito H; Inoue T
J Gastrointest Cancer; 2017 Dec; 48(4):326-332. PubMed ID: 27785685
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
Roth JA; Carlson JJ
J Gastrointest Cancer; 2012 Jun; 43(2):215-23. PubMed ID: 21234709
[TBL] [Abstract][Full Text] [Related]
4. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Rui M; Shi F; Shang Y; Meng R; Li H
Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy.
Kondo Y; Tachi T; Sakakibara T; Kato J; Mizuno T; Miyake Y; Teramachi H
J Pharm Health Care Sci; 2022 Jun; 8(1):15. PubMed ID: 35642015
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Ioka T; Kanai M; Kobayashi S; Sakai D; Eguchi H; Baba H; Seo S; Taketomi A; Takayama T; Yamaue H; Takahashi M; Sho M; Kamei K; Fujimoto J; Toyoda M; Shimizu J; Goto T; Shindo Y; Yoshimura K; Hatano E; Nagano H;
J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):102-110. PubMed ID: 35900311
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.
Zhao Q; Xie R; Zhong W; Liu W; Chen T; Qiu X; Yang L
Cost Eff Resour Alloc; 2023 Mar; 21(1):19. PubMed ID: 36859267
[TBL] [Abstract][Full Text] [Related]
13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.
Phippen NT; Leath CA; Chino JP; Jewell EL; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2012 Nov; 127(2):267-72. PubMed ID: 22892361
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan.
Kashiwa M; Matsushita R
BMC Health Serv Res; 2019 Jul; 19(1):438. PubMed ID: 31262292
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Chen X; Liang W; Wan N; Zhang L; Yang Y; Jiang J; Zhang T
Oral Oncol; 2019 Jul; 94():80-85. PubMed ID: 31178217
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China.
Zheng Z; Fang L; Cai H
BMC Cancer; 2023 Sep; 23(1):823. PubMed ID: 37667230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]